John Kiely insider trades: Amneal Pharmaceuticals (AMRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMRX | ↓ Sell | 50,000 | $17.64 | $882K | Direct | Aug 14, 2026 (1d) |
| Aug 27, 2025 | AMRX | ↓ Sell | 32,000 | $9.23 | $295K | Direct | Aug 28, 2025 (1d) |
| May 12, 2025 | AMRX | ↓ Sell | 50,000 | $7.59 | $380K | Direct | May 13, 2025 (1d) |
| Nov 22, 2024 | AMRX | ↓ Sell | 17,058 | $8.38 | $143K | Direct | Nov 26, 2024 (4d) |
| Sep 8, 2020 | ZVO | ↑ Buy | 10,000 | $4.26 | $43K | Direct | Sep 10, 2020 (2d) |
| May 19, 2020 | AMRX | ↑ Buy | 10,000 | $4.40 | $44K | Direct | May 19, 2020 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AMRX insiders
Open-market trades in the last 12 months
About John Kiely's insider trades
John Kiely is a director at Amneal Pharmaceuticals (AMRX). Since May 19, 2020, John has reported 2 open-market purchases worth $87K and 4 sales worth $1.7M on SEC Form 4. In the last 12 months: 1 sale ($882K).
Their filings also include option exercises (13 filings), grants and awards (11 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AMRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.